Rationale: The long-term evolution of patients with chest wall disease and chronic respiratory failure treated with noninvasive home mechanical ventilation (NIHMV) is poorly known. Objectives: The aim of this prospective observational study was to analyze the variables associated with mortality in a cohort of chest wall disease patients with chronic respiratory failure undergoing long-term follow-up after starting treatment with NIHMV. Methods: Chest wall disease patients who began NIHMV between 1996 and 2005 were followed up, with death as the primary outcome. The patients' clinical characteristics, lung function, and arterial blood gases were recorded at the start of treatment. Patients were seen and evaluated 1 month after starting NIHMV. The prognostic value of clinical and functional variables were assessed by Cox regression analyses. Main results: We included 110 patients, 61 with tuberculosis sequelae and 49 with kyphoscoliosis. By the end of follow-up, 34 patients (28%) had died. The 5-year survival was 69% in those with tuberculosis sequelae and 75% in kyphoscoliosis. PaCO 2 !50 mmHg at 1 month of home ventilation and comorbidity (Charlson Index !3) were independent predictors of mortality. Conclusion: Our results suggest that PaCO2 levels !50 mmHg at 1 month after starting noninvasive home mechanical ventilation and the presence of comorbid conditions are risk factors for mortality in patients with chest wall disease. The importance of early detection of suboptimal home ventilation as well as comorbidities is highlighted. 
Introduction
Noninvasive home mechanical ventilation (NIHMV) is indicated in chest wall diseases (CWD) developing chronic respiratory failure (CRF).
1,2 Therefore, in a European epidemiologic survey (Eurovent), CWD accounted for approximately one-third of the indications for home mechanical ventilation. 3 After implementation of NIHMV in CWD patients with CRF, improvements in hypoventilation symptoms 4, 5 and arterial blood gases (ABG), 6e10 and a reduction in hospital admissions due to respiratory complications 4, 9 have been shown. Despite these short-term favorable outcomes, the long-term evolution of NIHMV in these patients is poorly known. Survival in patients with CWD receiving NIHMV has been estimated in 2 series. 8, 10 Leger et al. 8 found that nearly 80% of patients continue NIHMV at 3 years. In the study by Simmonds et al., 10 this figure differed slightly depending on the cause of CWD: 94% and 79% of patients with tuberculosis sequelae and kyphoscoliosis, respectively, continued NIHMV at 5 years.
The relationship between clinical and respiratory function variables and mortality in CWD patients undergoing NIHMV remains to be defined. In a 10-year analysis from the ANTADIR Observatory, prognostic factors of mortality were evaluated in patients with tuberculosis sequelae and kyphoscoliosis. 11 However, less than 30% of these patients were receiving NIHMV, and the authors did not perform a separate analysis of this subsample. Taking into account all patients, regardless of the therapy received, female sex, younger age, a high body mass index, and higher PaO 2 and PaCO 2 values were all favorable independent prognostic factors. 11 Survival of patients with kyphoscoliosis 12 and tuberculosis sequelae 13 was also evaluated in the 2 Swedish studies mentioned above. In both studies, survival was associated with the therapy applied (NIHMV or LTOT) and this fact likely precluded the finding of associations between other independent variables and mortality. This paucity of evidence highlights the need for further studies focused on CWD patients undergoing NIHMV and followedup on a long-term basis. Knowledge of prognostic factors for mortality has clinical interest, since it may help to improve the management of these patients.
The aim of the present study was to analyze the variables associated with mortality in a cohort of patients with CWD and CRF undergoing long-term follow-up after starting treatment with NIHMV.
Patients and methods
All adult patients (!18 years) with CWD who started NIHMV in a teaching hospital (Vall dHebron Hospital, Barcelona, Spain) were considered for inclusion in this prospective, observational study. Patients were enrolled between January 1996 and December 2005. The indication for NIHMV was based on Spanish and international guidelines, 1, 14 including clinical symptoms (dyspnea, fatigue, orthopnea, or morning headache) and one of the following criteria: 1) stable patients with chronic hypercapnia (PaCO 2 >45 mmHg), 2) patients admitted due to acute hypercapnic respiratory failure requiring noninvasive mechanical ventilation, and 3) patients with oxygen saturation <90% during !30% of the night.
Patients with hypoventilation due to other respiratory diseases (neuromuscular, chronic obstructive pulmonary disease [COPD] , and obesity-hypoventilation syndrome) were not included in the study. Having a tracheostomy for airway access and discontinuation of NIHMV due to noncompliance were exclusion criteria. The flow chart for selecting patients is shown in Fig. 1 .
The study protocol was approved by the hospital ethics committee and written informed consent was obtained from all patients.
Variable measurements
Patients' characteristics were systematically recorded in a computer database. Forced spirometry 15 and static volumes (MasterLab Pro, Jaeger GmbH, Wuerzburg, Germany) were obtained according to the European Respiratory Society guidelines. 16 In stable patients, baseline respiratory function values were defined as the most recent ones obtained prior to initiating NIHMV. In patients who started NIHMV during acute respiratory failure, these values were obtained once the patient had stabilized before hospital discharge.
Samples for ABG testing were taken with the patient breathing room air and processed with a pH and blood gas analyser (IL-1306; Instrumentation Laboratories, Milan, Italy).
Comorbid conditions were recorded using the Charlson Index. 17 A score of 1e6 was assigned to each disease, depending on its associated risk of death. In this study, all patients had a minimal score of 1, since CWD was considered a chronic pulmonary disease.
Mechanical ventilation
NIHMV was initiated in the respiratory ward. Custom-made 8 or commercial nasal masks were used. The choice of Chest wall diseases n=115
Excluded from the study: Tracheostomy n=1 NIHMV withdrawal (noncompliance) n=4
Study population n=110 Figure 1 Flow chart of patient enrollment.
ventilator type was based on the criteria of the attending physician. 18 The ventilator parameters were set, and the efficacy of ventilation was evaluated taking into account the patient's tolerance, oxygen saturation, ABG while awake at 1 h after starting ventilation, and nocturnal pulse oximetry values.
14 Patients were instructed in the management of the ventilator and counseled in its progressive use, at least during the entire night.
Follow-up
All patients were seen in the hospital outpatient clinic 1 month after starting NIHMV, and at intervals of 3e6 months thereafter. At the 1-month visit, room-air ABG were measured. Compliance with the prescription was reported by the patient. A commercial supplier was in charge of providing technical support at the patients' home.
Patients remained in the study from the start of NIHMV up to closure of follow-up, in December 2007. Closure was earlier in patients who moved out of the study district. These patients were censored, but the information generated up to the time of closure was used in the study. The vital status and cause of death were obtained from the patients' medical files, relatives, or primary care physicians.
Statistical analysis
Assessment of baseline homogeneity between survivors and deceased patients was performed with the unpaired t-test for continuous variables, the ManneWhitney test for ordinal variables, and Fisher's exact test for qualitative variables. Results are expressed as the mean AE SD for quantitative variables, and as frequencies and percentages for qualitative and ordinal variables. The KaplaneMeier method was used to estimate the survival functions and the Cox proportional hazards model was used to perform the adjusted analysis.
The selection of independent variables for multivariate Cox model was based on statistical significance obtained in the univariate analysis (p < 0.10). A forward stepwise procedure was used and results are expressed as hazard ratios with 95% confidence intervals (CI).
Analyses were performed with SPSS for Windows, 15.0 (Statistical Package for the Social Sciences, Chicago, IL, USA). Statistical significance for all tests was set at a twotailed p-value of 0.05.
Results

Clinical characteristics
Among 115 CWD patients starting NIHMV during 1996e2005, 110 were included in the study (Fig. 1) . Characteristics of the patients as a group and according to their vital status at follow-up closure are shown in Table 1 . At baseline, the study cohort included 58% men with a mean age of w66 years. Spirometry showed a severe restrictive ventilatory impairment with associated obstruction (FEV1/FVC <0.7) in 52 patients (47.3%). Obstruction was more prevalent in the group with tuberculosis sequelae (60.7%) than in those with kyphoscoliosis (30.6%) (p Z 0.002). Over 75% of participants had at least one comorbid condition in addition to respiratory disease (i.e., Charlson Index !2).
Noninvasive home mechanical ventilation was started during an admission for respiratory exacerbation in 17 patients (15.5%). Among the stable patients, NIHMV was indicated with PaCO 2 <45 mmHg in 6 cases (5.5%). Ninetythree patients (84.5%) were treated with volume-cycled ventilators and 17 (15.5%) with pressure-cycled ventilators. Assist-control mode was used in 59 patients (53.6%), and control mode in the remaining 51 (46.4%). In order to overcome oral leaks, a chin strap was prescribed in 4 patients (3.6%). Twenty-four patients (21.8%) needed oxygen coupled to the ventilator. Baseline PaO 2 and PaCO 2 indicated hypercapnic respiratory failure (PaO 2 55.6 AE 11.2 and PaCO 2 56.4 AE 9.0 mmHg) ( Table 1) . During mechanical ventilation, PaCO 2 returned to normal levels 1 h after starting therapy (41.3 AE 7.6 mmHg); 1 month later, with the patient using home ventilation, diurnal PaCO 2 was maintained at 46.4 AE 4.9 mmHg while breathing room air.
Follow-up and mortality
Patients were followed-up for a median of 4.6 years (interquartile range, 2.4e6.0). In 2 survivors who moved to a different region, follow-up ended before December 2007, at 7 and 23 months after starting NIHMV, respectively. Another patient presented acute respiratory failure 9 years after initiating NIHMV via nasal mask, and ventilation was continued via tracheostomy. No patients were lost to follow-up. The mean 1-month patient-reported compliance with therapy was 9.3 AE 1.9 h/day (9.6 AE 1.8 in survivors vs. 8.8 AE 2.0 in non-survivors p Z 0.055).
By the end of follow-up, 34 of 110 patients had died (28.1%). Deaths were mainly due to respiratory causes (64.7%) ( Table 2 ). In the univariate analysis, patients who died had higher comorbidity, total lung capacity, residual volume, and PaCO 2 at 1 month, and lower FEV 1 , FEV 1 /FVC ratio, and PaO 2 at 1 month (Table 1 ). There were no differences in ventilation characteristics, such as ventilator type (volume-vs. pressure-cycled) or mode (assist-control vs. control), between survivors and non-survivors (p Z 0.776 and p Z 0.303, respectively). There were no differences in survival between patients with tuberculosis sequelae and those with kyphoscoliosis ( Table 1 ). The 5-year survival rate was 0.69 (95% CI 0.55e0.83) in patients with tuberculosis sequelae and 0.75 (0.60e0.89) in those with kyphoscoliosis.
Multivariate Cox analysis identified comorbidity and PaCO 2 at 1 month as independent predictors of mortality ( Table 3 ). The risk of death at least doubled with a Charlson score !3, assuming the lower limit of the 95% CI as the minimum risk associated with the present data. Regarding PaCO 2 value at 1 month, we defined several meaningful cutoff points, such as 40, 45, and 50 mmHg (Table 4) . A 1-month PaCO 2 of !50 mmHg yielded a more than 3-fold increase in the probability of death. KaplaneMeier survival curves for all-cause mortality according to PaCO 2 at 1 month are shown in Fig. 2 .
Discussion
In this study, a PaCO 2 value of !50 mmHg at 1 month after starting ventilation and the presence of comorbid conditions as assessed by the Charlson Index were predictive factors for mortality in a cohort of CWD patients treated with NIHMV.
Chest wall disease is a frequent cause of respiratory failure. The available data have shown considerable longterm mortality in patients with CWD, particularly those treated with LTOT. 12, 13 NIHMV is an effective treatment for ventilatory failure in CWD patients, but few studies have focused on the long-term survival of this population and the factors associated with mortality. The fact that a percentage of our patients died during follow-up despite treatment with NIHMV prompted us to investigate this issue.
Our finding that an elevated PaCO 2 at 1 month after starting NIHMV is associated with mortality seems clinically a Sepsis (n Z 2), intestinal occlusion (n Z 2), and chronic renal failure (n Z 1). Values are given as the mean AE SD or n (%), unless otherwise indicated. % pred Z % predicted; BMI Z body mass index; FVC Z forced vital capacity; FEV 1 Z forced expiratory volume in 1 s; TLC Z total lung capacity; RV Z residual volume; PaO 2 Z arterial oxygen tension; PaCO 2 Z arterial carbon dioxide tension; D(A-a)O 2 Z alveolar-arterial oxygen difference. *p < 0.05. a Mainly thoracoplasty and artificial pneumothorax. b n Z 109.
relevant. Arterial blood gas status before NIHMV has been investigated in most studies 11e13 but the prognostic value of PaCO 2 after starting NIHMV is poorly known. In a recently online published study, 19 the relationship between post-NIHMV variables and withdrawal of this treatment in a Japanese cohort of patients with tuberculosis sequelae was analyzed. The authors found that PaCO 2 levels at 3e6 months were associated with rates of NIHMV continuation. The main difference between this cohort and ours is the severity of the baseline hypercapnia at starting ventilation, which was higher in the former. So, while baseline mean PaCO 2 in our patients was 56.4, it ranged between 64.6 and 90.2 mmHg in the Japanese cohort. Moreover, 50% of these patients had PaCO 2 levels higher than 60 mmHg at 3e6 months post-NIHMV. In spite of these differences, both studies point out the relevance of PaCO 2 measurement in the control of patients stabilized after NIHMV instauration. The need to check blood gases early in the follow-up of these patients seems reasonable, because the initial response observed during hospital admission should be reassessed once ventilation is used at home. Hence, delayed gasometric evaluation of NIHMV efficacy may better reflect the patients' response to NIHMV.
20 Some patients need a longer period of time to adapt to ventilation, and in others delayed problems of leaks, compliance, or patient-ventilator asynchrony may appear. According to our results, inability to maintain PaCO 2 <50 mmHg after 1 month of NIHMV may be a reflection of these problems or simply indicate the limitation of this therapy to revert respiratory failure in certain patients, thus justifying their higher mortality. This is supported by the fact that 65% of the deaths had a respiratory origin. ABG before starting ventilation were not associated with mortality in our study. This data likely express baseline severity, but their prognostic value is unclear, because NIHMV was effective in reverting ventilatory failure in most cases, and therefore, the problem threatening the patients' evolution would have been modified. Our results highlight the value of short-term surveillance that includes ABG measurement in the management of CWD patients undergoing NIHMV. This suggests that home ventilation should be checked early after it is started and readjusted when hypercapnia is detected.
We observed a consistent, progressive relationship between comorbidity expressed with the Charlson Index and mortality. Comorbidity is likely to influence mortality in several ways. First, it may have provoked an increase in the percentage of fatal nonrespiratory complications, since 35% of deaths were not related to respiratory causes. Second, the presence of comorbid conditions could make a patient more susceptible to respiratory exacerbations, 21 which were the most common cause of death in our series. And last, the presence of additional diseases might have a deleterious effect on the efficacy of NIHMV or make compliance more difficult. In any case, our results indicate the need for a careful, comprehensive evaluation of patients with CWD to improve their overall health status and not only limit the therapeutic effort to reverting ventilatory failure.
The patients undergoing NIHMV in the present study had a severe restrictive ventilatory pattern, and in 47.3% of cases, mainly those with tuberculosis sequelae, airway obstruction was also present. Obstruction has been described as a functional respiratory complication after tuberculosis. 22, 23 Among our post-tuberculosis patients with this complication, the functional impairment was likely due to tuberculosis alone in 44% of patients, while smoking could have been a contributory factor in the 56% remainder. We attempted to ascertain the influence of airway obstruction on mortality in the 110 patients studied. Although a significant difference was seen in the univariate approach, there was no association between obstruction and mortality in the multivariate model. The reason why obstruction did not influence mortality may be due to the fact that this impairment was appropriately treated.
The present study has several potential limitations. The lengthy period of inclusion and follow-up, necessarily required in a survival study, implies that changes in the management of the population included may have occurred over time. For example, the current indications for NIHMV include patients with obesity-hypoventilation syndrome and some patients with COPD. Nonetheless, the indications for ventilatory support in CWD have remained stable over the years, 24 ,25 and we do not believe this factor posed a problem in the study. Another potentially conflicting point is the type of ventilator used. Classically, patients with CWD have been treated with volume-cycled ventilators, 3 but in recent years there has been an increasing use of pressure-cycled ventilators. 25 In our study, pressurecycled ventilators were used in only 15% of the patients. The scientific evidence reported to date has not shown differences in the efficacy of ventilation depending on the type of cycling 26 ; thus, it is reasonable to assume that this variable would not have an influence on survival. Notwithstanding, we believe the prognostic data obtained in our study should be confirmed in CWD patients who are mainly treated with pressure-cycled ventilators.
In conclusion, our results suggest that PaCO 2 levels !50 mmHg at 1 month after starting noninvasive home mechanical ventilation and the presence of comorbid conditions are risk factors for mortality in patients with chest wall disease. We believe these results are relevant for the clinical management of these patients, particularly because they underscore the importance of early detection of suboptimal home ventilation, which may be amenable to correction.
